SCHEMBL369361

SCHEMBL369361

CCC(=O)c1nn(Cc2ccc(OC)cc2)cc1-c1nc(NC(=O)OC(C)(C)C)sc1C=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
MAPT P10636 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MKNK2 Q9HBH9 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 2/20 0.35
ADORA3 P0DMS8 2/20 0.34
CACNA1H O95180 1/20 0.34
ACHE P22303 1/20 0.34
NPC1 O15118 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
GAA P10253 1/20 0.34
LCK P06239 1/20 0.34
SCD O00767 1/20 0.34
RAB9A P51151 1/20 0.33
CFTR P13569 1/20 0.33
XBP1 P17861 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6837114 0.91 MKNK2 (0.42) HDAC3HDAC8NCOR2MAPTMEN1
SCHEMBL370192 0.87 MAPT (0.35) HDAC3HDAC8NCOR2MAPTMEN1
SCHEMBL370868 0.86 MKNK2 (0.35) HDAC3HDAC8NCOR2MAPTMEN1
SCHEMBL371073 0.84 MAPT (0.34) HDAC3HDAC8NCOR2MAPTMEN1
SCHEMBL369851 0.80 GSK3A (0.40) HDAC3HDAC8NCOR2MAPTMEN1
SCHEMBL369206 0.80 GSK3B (0.40) HDAC3HDAC8NCOR2MAPTMEN1
SCHEMBL370992 0.80 LMNA (0.36) HDAC3HDAC8NCOR2MAPTMKNK2
SCHEMBL6837480 0.79 RXFP1 (0.42) HDAC3HDAC8NCOR2MAPTMEN1
SCHEMBL6837270 0.78 LCK (0.38) HDAC3HDAC8NCOR2MAPTLMNA
SCHEMBL6837466 0.77 LCK (0.36) HDAC3HDAC8NCOR2MAPTMKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 HDAC3 520/4885HDAC8 1145/4885NCOR2 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.